| Similar Articles |
|---|
 |
The Motley Fool
December 4, 2006
Michael P. Cecil |
Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy?   |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
BusinessWeek
November 24, 2010
Tom Randall |
Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent. |
The Motley Fool
June 27, 2005
Brian Gorman |
Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note. |
The Motley Fool
February 22, 2007
Brian Lawler |
Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today. |
The Motley Fool
August 30, 2007
Brian Orelli |
Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
November 15, 2011
Brian Orelli |
Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck. |
The Motley Fool
December 4, 2006
Michael Leibert |
Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors. |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
The Motley Fool
January 23, 2007
Ryan Fuhrmann |
Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009. |
Chemistry World
January 2007
Derek Lowe |
Opinion: In the Pipeline Here is a look at the recent failure of Pfizer's cholesterol drug, torcetrapib, and what it could mean for the future of pharmaceutical research. |
The Motley Fool
April 5, 2005
Stephen D. Simpson |
Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be? |
Pharmaceutical Executive
February 1, 2009
Flamenbaum et al. |
Stream Power Convert future revenue into present value with alternative approaches to access capital. |
